https://www.selleckchem.com/pr....oducts/poly-l-lysine
Introduction Statin intensification is required in patients who have high-risk for cardiovascular events. However, it is unclear if this is needed in whom plasma LDL-C target was achieved with low-dose statin for primary prevention. We investigated the efficacy and safety of switching from low-dose statin to high-intensity statin among type 2 diabetes (T2D) who had achieved plasma LDL-C less then 100 mg/dl with low-dose statin treatment. Methods T2D patients with no atherosclerotic cardiovascular disease who had plasma LDL-C level
Like
Comment
Share
